Search results
Results From The WOW.Com Content Network
File:Novartis-Logo.svg. Size of this PNG preview of this SVG file: 512 × 84 pixels. Other resolutions: 320 × 53 pixels | 640 × 105 pixels | 1,024 × 168 pixels | 1,280 × 210 pixels | 2,560 × 420 pixels. Original file (SVG file, nominally 512 × 84 pixels, file size: 2 KB) This is a file from the Wikimedia Commons.
Novartis. / 47.5744252; 7.5764914. Pharmaceutical drugs, generic drugs, over-the-counter drugs, vaccines, diagnostics, contact lenses, animal health ( list...) Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical ...
Chiron Corporation ( / ˈkaɪrɒn / KY-ron) [1] was an American multinational biotechnology firm founded in 1981, based in Emeryville, California, that was acquired by Novartis on April 20, 2006. It had offices and facilities in eighteen countries on five continents. Chiron's business and research was in three main areas: biopharmaceuticals ...
Vasant "Vas" Narasimhan (born August 26, 1976) is an American physician and the chief executive officer of Novartis. He succeeded Joseph Jimenez who left Novartis in 2018. He briefly worked at McKinsey before joining Novartis in 2005, where he has held a range of leadership roles, including Global Head of Development for Novartis Vaccines and Global Head of Drug Development & Chief Medical ...
The Novartis Foundation was a scientific and educational charity, formed in 1949 by the Swiss company Ciba, now Novartis, and dissolved in 2008. It was the direct successor to the Ciba Foundation, and the changed name (Novartis Foundation) reflected the new name of Ciba, after merging with Sandoz. The Foundation was the brainchild of Robert ...
Alpelisib. Alpelisib, sold under the brand name Piqray among others, is a medication used to treat certain types of breast cancer. [8] It is used together with fulvestrant. [8] It is taken by mouth. [8] It is marketed by Novartis.
Brolucizumab was designed to attach to and block a substance called vascular endothelial growth factor A (VEGF-A). [6] VEGF-A is a protein that makes blood vessels grow and leak fluid and blood, damaging the macula. By blocking VEGF-A, brolucizumab reduces the growth of the blood vessels and controls the leakage and swelling.
Medical bottles and syringe are seen with Novartis logo displayed on a screen in the background in this illustration photo taken in Krakow, Poland on November 10, 2022.